CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549

• Autorzy: Roudi R. , Madjd Z. , Ebrahimi M. , Samani F. S. , Samadikuchaksaraei A.
• Języki publikacji: EN

Abstrakty

EN

Cancer stem cells (CSCs) are subpopulations of tumor cells that are responsible for tumor initiation, maintenance and metastasis. Recent studies suggested that lung cancer arises from CSCs. In this study, the expression of potential CSC markers in cell line A549 was evaluated. We applied flow cytometry to assess the expression of putative stem cell markers, including aldehyde dehydrogenase 1 (ALDH1), CD24, CD44, CD133 and ABCG2. Cells were then sorted according to the expression of CD44 and CD24 markers by fluorescence-activated cell sorting (FACS) Aria II and characterized using their clonogenic and sphere-forming capacity. A549 cells expressed the CSC markers CD44 and CD24 at 68.16% and 54.46%, respectively. The expression of the putative CSC marker ALDH1 was 4.20%, whereas the expression of ABCG2 and CD133 was 0.93%. Double-positive CD44/133 populations were rare. CD44+/24+ and CD44+/CD24−/low subpopulations respectively exhibited 64% and 27.92% expression. The colony-forming potentials in the CD44+/CD24+ and CD44+/CD24−/low subpopulations were 84.37 ± 2.86% and 90 ± 3.06%, respectively, while the parental A549 cells yielded 56.65 ± 2.33% using the colony-formation assay. Both isolated subpopulations formed spheres in serumfree medium supplemented with basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF). CD44 and CD24 cannot be considered potential markers for isolating lung CSCs in cell line A549, but further investigation using in vivo assays is required.

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2014
• Tom: 19
• Numer: 1
• Opis fizyczny: p.23-36,fig.,ref.

Twórcy

autor

Roudi R.

• Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Inran University of Medical Sciences, Teheran, Iran
• Department of Steam Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Teheran, Iran
• Cellular and Molecular Research Center, Iran University of Medical Sciences, Teheran, Iran

autor

Madjd Z.

• Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Inran University of Medical Sciences, Teheran, Iran
• Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran
• Cellular and Molecular Research Center, Iran University of Medical Sciences, Teheran, Iran

autor

Ebrahimi M.

• Department of Steam Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Teheran, Iran

autor

Samani F. S.

• Department of Steam Cells and Developmental Biology at Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Teheran, Iran

autor

Samadikuchaksaraei A.

• Cellular and Molecular Research Center, Iran University of Medical Sciences, Teheran, Iran
• Department of Medical Biotechnology, Iran University of Medical Sciences, Teheran, Iran

Bibliografia

• 1.Travis, W.D. Pathology of lung cancer. Clin. Chest. Med. 32 (2011) 669- 692.
• 2. Boman, B.M. and Wicha, M.S. Cancer stem cells: a step toward the cure. J. Clin. Oncol. 26 (2008) 2795-2799.
• 3. Jordan, C.T., Guzman, M.L. and Noble, M. Cancer stem cells. N. Engl. J. Med. 355 (2006) 1253-1261.
• 4. Reya, T., Morrison, S.J., Clarke, M.F. and Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111.
• 5. Rivera, C., Rivera, S., Loriot, Y., Vozenin, M.C. and Deutsch, E. Lung cancer stem cell: new insights on experimental models and preclinical data. J. Oncol. 2011 (2011) 549181.
• 6. Sun, S., Schiller, J.H., Spinola, M. and Minna, J.D. New molecularly targeted therapies for lung cancer. J. Clin. Invest. 117 (2007) 2740-2750.
• 7. Bertolini, G., Roz, L., Perego, P., Tortoreto, M., Fontanella, E., Gatti, L., Pratesi, G., Fabbri, A., Andriani, F. , Tinelli, S., Roz, E., Caserini, R., Lo Vullo, S., Camerini, T., Mariani, L., Delia, D., Calabrò, E., Pastorino, U. and Sozzi, G. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA 106 (2009)16281-16286.
• 8. Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., Conticello, C., Ruco, L., Peschle, C. and De Maria, R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15 (2007) 504-514.
• 9. Piechaczek, C. CD133. J. Biol. Regul. Homeost. Agents 15 (2001) 101-102.
• 10. Chen, Y.C., Hsu, H.S., Chen, Y.W., Tsai, T.H., How, C.K., Wang, C.Y., Hung, S.C., Chang, Y.L., Tsai, M.L., Lee, Y.Y., Ku, H.H. and Chiou, S.H. Oct-4 expression maintained cancer stem-like properties in lung cancerderived CD133-positive cells. PLoS One 3 (2008) e2637.
• 11. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J. and Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100 (2003) 3983-3988.
• 12. Leung, E.L., Fiscus, R.R., Tung, J.W., Tin, V.P., Cheng, L.C., Sihoe, A.D., Fink, L.M., Ma, Y. and Wong, M.P. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 5 (2010) e14062.
• 13. Naor, D., Wallach-Dayan, S.B., Zahalka, M.A. and Sionov, R.V. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin. Cancer Biol. 18 (2008) 260-267.
• 14. Hurt, E.M., Kawasaki, B.T., Klarmann, G.J., Thomas, S.B. and Farrar, W.L. CD44+ CD24 - prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 98 (2008) 756-765.
• 15. Yeung, T.M., Gandhi, S.C., Wilding, J.L., Muschel, R. and Bodmer, W.F. Cancer stem cells from colorectal cancer-derived cell lines Proc. Natl. Acad. Sci. USA 107 (2010) 3722-3727.
• 16. Yoshida, A., Hsu, L. and Dave, V. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme 46 (1992) 239-244.
• 17. Jiang, F., Qiu, Q., Khanna, A., Todd, N.W., Deepak, J., Xing, L., Wang, H., Liu, Z., Su, Y., Stass, S.A. and Ktz, R.L. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 7 (2009) 330-338.
• 18. Ucar, D., Cogle, C.R., Zucali, J.R., Ostmark, B., Scott, E.W., Zori, R., Gray, B.A. and Moreb, J.S. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem. Biol. Interact 178 (2009) 48-55.
• 19. Ding, X.W., Wu, J.H. and Jiang, C.P. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 86 (2010) 631-637.
• 20. Ho, M.M., Ng, A.V., Lam, S. and Hung, J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67 (2007) 4827-4833.
• 21. Charloux, A., Quoix, E., Wolkove, N., Small, D., Pauli, G. and Kreisman, H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int. J. Epidemiol. 26 (1997) 14-23.
• 22. Sung, J.M., Cho, H.J., Yi, H., Lee, C.H., Kim, H.S., Kim, D.K., Abd El-Aty, A.M., Kim, J.S., Landowski, C.P., Hediger, M.A. and Chin, H.C. Characterization of a stem cell population in lung cancer A549 cells. Biochem. Biophys. Res. Commun. 371 (2008) 163-167.
• 23. Barrandon, Y. and Green, H. Three clonal types of keratinocyte with different capacities for multiplication. Proc. Natl. Acad. Sci. USA 84 (1987) 2302-2306.
• 24. Li, H., Chen, X., Calhoun-Davis, T., Claypool, K. and Tang, D.G. PC3 human prostate carcinoma cell holoclones contain self-renewing tumorinitiating cells. Cancer Res. 68 (2008) 1820-1825.
• 25. Zhou, Z.H., Ping, Y.F., Yu, S.C., Yi, L., Yao, X.H., Chen, J.H., Cui, Y.H. and Bian, X-W. A novel approach to the identification and enrichment of cancer stem cells from a cultured human glioma cell line. Cancer Lett. 281 (2009) 92-99.
• 26. Tan, L., Sui, X., Deng, H. and Ding, M. Holoclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cells. PLoS One 6 (2011) e23383.
• 27. Franken, N.A., Rodermond, H.M., Stap, J., Haveman, J. and Van Bree, C. Clonogenic assay of cells in vitro. Nat. Protoc. 1 (2006) 2315-2319.
• 28. Pastrana, E., Silva-Vargas, V. and Doetsch, F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8 (2011) 486-498.
• 29. Friedrich, J., Seidel, C., Ebner, R. and Kunz-Schughart, L.A. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 4 (2009) 309-324.
• 30. Hill, R.P. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res. 66 (2006) 1891-1895.
• 31. Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D. and Dirks, P.B. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401.
• 32. Meng, X., Li, M., Wang, X., Wang, Y. and Ma, D. Both CD133+ and CD133 - subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci. 100 (2009) 1040-1046.
• 33. Akunuru, S, Zhai, Q.J. and Zheng, Y. Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis. 3 (2012) e352.
• 34. Stuelten, C.H., Mertins, S.D., Busch, J.I., Gowens, M., Scudiero, D.A., Burkett, M.W., Hite, K.M., Alley, M., Hollingshead, M., Shoemaker, R.H. and Niederhuber, J.E. Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cells 28 (2010) 649-660.
• 35. Levina, V., Marrangoni, A.M., DeMarco, R., Gorelik, E. and Lokshin, A.E. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3 (2008) e3077.
• 36. Tirino, V., Camerlingo, R., Franco, R., Malanga, D., La Rocca, A., Viglietto, G., Rocco, G. and Pirozzi, G. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-smallcell lung cancer. Eur. J. Cardiothorac. Surg. 36 (2009) 446-453.
• 37. Fargeas, C., Huttner, W. and Corbeil, D. Nomenclature of prominin-1 (CD133) splice variants-an update. Tissue Antigens 69 (2007) 602-606.
• 38. Shmelkov, S.V., St Clair, R., Lyden, D. and Rafii, S. AC133/CD133/Prominin-1. Int. J. Biochem. Cell Biol. 37 (2005) 715-719.
• 39. Wang, P., Gao, Q., Suo, Z., Munthe, E., Solberg, S., Ma, L., Wang, M., Westerdaal, N.A., Kvalheim, G. and Gaudernack, G. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One 8 (2013) e57020.
• 40. Kim, J., Jung, J., Lee S.J., Lee J.S. and Park M.J. Cancer stem-like cells persist in established cell lines through autocrine activation of EGFR signaling. Oncol. Lett. 3 (2012) 607-612.
• 41. Kelly, J.J., Stechishin, O., Chojnacki, A., Lun, X., Sun, B., Senger, D.L., Forsyth, P., Auer, R.N., Dunn, J.F., Cairncross, J.G. , Parney I.F., and Weiss, S. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells 27 (2009) 1722-1733.
• 42. Li, G., Chen, Z., Hu, Y.D., Wei, H., Li, D., Ji, H. and Wang, D-L. Autocrine factors sustain glioblastoma stem cell self-renewal. Oncol. Rep. 21 (2009) 419-424